id: civic.eid:879
description: A phase III clinical trial (NCT00949650) found that median progression
  free survival among patients with exon 19 deletions or L858R EGFR mutations (n
  = 308) was 13.6 months for afatinib and 6.9 months for chemotherapy (HR, 0.47;
  95% CI, 0.34 to 0.65; P = 0.001).
direction: supports
evidence_level:
  id: vicc:e00003
  label: Clinical trial or cohort study
  type: Coding
target_proposition: proposition:nefbQvxqptMo6fBTdwsYsJpDkSSQeTGj
variation_origin: somatic
subject_descriptor: civic.vid:33
object_descriptor: civic.tid:146
neoplasm_type_descriptor: civic.did:30
method: metakb.method:1
is_reported_in: [ "civic.source:592" ]
type: VariationTherapeuticResponseStatement
